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Abstract
Background: An outbreak of pneumococcal meningitis among non-infant children and adults occurred in the
Brong-Ahafo region of Ghana between December 2015 and April 2016 despite the recent nationwide implementation
of a vaccination programme for infants with the 13-valent pneumococcal conjugate vaccine (PCV13).
Methods: Cerebrospinal fluid (CSF) specimens were collected from patients with suspected meningitis in the
Brong-Ahafo region. CSF specimens were subjected to Gram staining, culture and rapid antigen testing. Quantitative
PCR was performed to identify pneumococcus, meningococcus and Haemophilus influenzae. Latex agglutination and
molecular serotyping were performed on samples. Antibiogram and whole genome sequencing were performed on
pneumococcal isolates.
Results: Eight hundred eighty six patients were reported with suspected meningitis in the Brong-Ahafo region during
the period of the outbreak. In the epicenter district, the prevalence was as high as 363 suspected cases per 100,000
people. Over 95 % of suspected cases occurred in non-infant children and adults, with a median age of 20 years.
Bacterial meningitis was confirmed in just under a quarter of CSF specimens tested. Pneumococcus, meningococcus
and Group B Streptococcus accounted for 77 %, 22 % and 1 % of confirmed cases respectively. The vast majority of
serotyped pneumococci (80 %) belonged to serotype 1. Most of the pneumococcal isolates tested were susceptible to
a broad range of antibiotics, with the exception of two pneumococcal serotype 1 strains that were resistant to both
penicillin and trimethoprim-sulfamethoxazole. All sequenced pneumococcal serotype 1 strains belong to Sequence
Type (ST) 303 in the hypervirulent ST217 clonal complex.
(Continued on next page)
* Correspondence: mantonio@mrc.gm
†Equal contributors
1Vaccines and Immunity Theme, The Medical Research Council Unit The
Gambia, P.O Box 273, Banjul, Fajara, The Gambia
7Microbiology and Infection Unit, Warwick Medical School, Warwick, UK
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Kwambana-Adams et al. BMC Infectious Diseases  (2016) 16:575 
DOI 10.1186/s12879-016-1914-3
(Continued from previous page)
Conclusion: The occurrence of a pneumococcal serotype 1 meningitis outbreak three years after the introduction of
PCV13 is alarming and calls for strengthening of meningitis surveillance and a re-evaluation of the current vaccination
programme in high risk countries.
Keywords: Pneumococcus, Outbreak, Serotype 1, Ghana, Meningitis belt, West Africa, Meningitis, Pneumococcal
conjugate vaccine (PCV)
Background
Acute bacterial meningitis is most commonly caused by
Neisseria meningitidis, Streptococcus pneumoniae and
Haemophilus influenzae Type b. In sub-Saharan Africa,
there is a “meningitis belt” running from Ethiopia to
Senegal where there is high seasonal incidence of bacterial
meningitis. In West Africa, the highest incidence of bac-
terial meningitis occurs during the dry season (December
to March) [1–3], with incidence rates in epidemics as high
as 800 cases per 100,000 people [4, 5].
N. meningitidis, the meningococcus, is the leading cause
of bacterial meningitis in West Africa after the first year of
life, even in non-epidemic periods [1–3, 6, 7]. In the past,
most West African meningococcal outbreaks were attrib-
uted to serogroup A [8]. However, the MenAfriVac™ vac-
cine, which protects against meningococcal serogroup A,
has been rolled out in several countries in the meningitis
belt. In Ghana, MenAfriVac™ vaccination campaigns con-
ducted in 2012 covered the three northern regions within
the meningitis belt [4].
Outbreaks of S. pneumoniae, the pneumococcus, were
previously thought to be restricted to prisons, military
camps and among people living in crowded conditions
such as refugee camps [9–13]. However, in the early
2000s, large pneumococcal outbreaks were reported in a
few West African countries including Ghana [3, 14–16].
A sustained increase in the cases of pneumococcal men-
ingitis was reported in Northern Ghana between 2000
and 2003. The incidence of pneumococcal meningitis rose
from ≤5 cases/100,000 people/year in 2000 to 15–26
cases/100,000 people/year at its peak [16]. Pneumococcal
meningitis outbreaks were also reported in neighboring
countries Burkina Faso, Togo and Niger around the same
period [3, 14–16]. These West-African outbreaks have
been characterised by high case-fatality rates (up to 40 %)
and appear to mimic meningococcal meningitis outbreaks,
with peaks in the hot dry season [3, 14, 16]. Pneumococci
expressing the serotype 1 capsule dominated the West
African pneumococcal meningitis outbreaks. Most of the
strains belonged to the clonal complex dominated by
Sequence Type (ST)217 [14, 16, 17].
The 13-valent pneumococcal polysaccharide-diphtheria
CRM197 protein conjugate vaccine (PCV13) now part of
the routine immunization programmes in many countries
is particularly efficacious in infants. PCVs are thought to
elicit mucosal immunity, possibly due to the induction of
opsonizing IgA antibodies [18]. Widespread use of PCVs
markedly reduces carriage of vaccine serotypes amongst
both vaccinated and unvaccinated individuals [19–21].
PCVs are a remarkable public health success as they in-
duce herd immunity and are associated with reductions in
invasive pneumococcal disease globally [19–21]. PCV13
was introduced in the Ghana Expanded Programme on
Immunisation (EPI) in April 2012.
The Brong Ahafo Region spans the central section of
Ghana on the north–south axis and falls outside the
meningitis belt, which is restricted to the northern region
of the country. The WHO designated Regional Reference
Laboratory (RRL) hosted at the Medical Research Council
Unit The Gambia coordinates surveillance of invasive
bacterial diseases across West Africa. The WHO RRL
supported the Ghana Ministry of Health to confirm the
causative pathogens and provided technical laboratory
support teams at regional and district hospitals in the
Brong Ahafo Region for bacteriologic processing of
CSF specimens. The aim of this study was to confirm
and characterise the pathogens that caused this unusual
outbreak in Ghana.
Methods
Study area
The Brong-Ahafo Region is one of ten regions in Ghana
and has a population of 2.4 million distributed in 27 dis-
tricts. It has a bi-modal rainfall pattern with the major rainy
season occurring between April and July and a minor rainy
season between September and October. The dry season
runs from November to March.
Patients
All cases of suspected meningitis in Brong Ahafo Region,
which presented at private, mission, district and regional
hospitals had a lumbar puncture performed. Suspected
meningitis was defined as sudden onset of fever (>38.5 °C)
and a combination of any of the following clinical symp-
toms: reduced level of consciousness, stiff neck, bulging
fontanel, fit(s) if aged between six months and five years
or partial seizures. When available, the CSF specimens
were stored in Trans-isolate (T-I) media. The patients
were treated with ceftriaxone or ampicillin.
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Bacteriologic analysis of CSF specimens
CSF samples were initially processed at the health centers
or hospitals where they were collected. However, when
this was not possible, the processing was performed at the
Regional Hospital, Sunyani. The primary method for the
detection of pneumococcus, Haemophilus influenzae type
b, meningococcus serogroups A, C, Y/W was the Pastorex
meningitis kit (Biorad, UK), which was used following
manufacturer’s instructions.
For culture, 10 μl of un-centrifuged CSF was streaked
onto Columbia blood agar (BA) and chocolate agar (CA)
plates and incubated at 37 °C in 5 % CO2 for 18–24 h
(overnight). 1–2 drops of CSF were used to prepare a
smear, air-dried and fixed by flooding with 95 % ethanol for
2 min or by passing through the flame for a few seconds.
Gram stain was performed following WHO protocol [22].
Following overnight incubation, the CA and BA plates
were examined for characteristic growth of pneumococcus,
H. influenzae, meningococcus and other pathogens.
Suspected pneumococcal colonies were confirmed and
serotyped as previously described [23]. All suspected
meningococcus or H. influenzae underwent biochemical
confirmation using analytical profile index kits (API NH;
Biomerieux, UK). Meningococcal serogroups were assessed
by use of the Directigen™ meningitis combo kit (Oxoid
Basingstoke, UK) following manufacturer’s instructions.
Pneumococcal isolates underwent antibiotic susceptibility
testing by the disc and E-test diffusion methods for com-
monly prescribed antibiotics in the sub-region following
CSLI guidelines [24]. Antibiotic activity in the CSF speci-
mens was assessed by the disc diffusion antibiotic bioassay
following the method described previously by Driscoll et al.,
(2012) [25]. All antibiotics were procured from Oxoid
(Basingstoke, UK) and E-test strips from Biomerieux, UK.
The MRC Unit The Gambia, molecular microbiology
laboratory submits to the external quality assurance
programme of the UK National External Quality As-
sessment Service (http://www.ukneqas.org.uk) and is a
World Health Organization (WHO) Regional Refer-
ence Laboratory for invasive bacterial pathogens.
Real time PCR detection and serotyping of pathogens
An aliquot of the CSF specimens was shipped to the
WHO RRL hosted at MRCG in dry ice (−80 °C). Species-
specific quantitative PCR (qPCR) assays for detection of
pneumococcus, meningococcus and H. influenzae were
conducted using the autolysin gene (lytA), the CU, Zn
superoxide dismutase gene (sodC) and the protein D en-
coding gene (hpd) respectively as previously described
[26–28]. RNaseP gene assay was performed on all CSF
specimens to confirm samples of human origin and the
integrity of the CSF specimens. Positivity for each of the
targets was deduced using cycle threshold (CT) values.
CTs of ≤36 were considered as positive.
Serogroup and serotype specific qPCR assays
Meningococcal serogrouping and H. influenzae serotyping
were performed by direct qPCR as previously described
[27]. Targets for the mentioned pathogens included sacB,
synD, synE, synG, xcbB, synF genes for serogroups A, B, C,
W, X, Y respectively. For H. influenzae, the following sero-
types were screened: acB (Hia), bcsB (Hib), ccsD (Hic),
dscE (Hid), ecsH (Hie) and bexD (Hif).
Streptococcus pneumoniae serotyping
In preparation for nucleic acid extraction for pneumococ-
cal serotyping, 200 μL of CSF was added to 50 μL of TE
buffer containing 0.08 g/mL of lysozyme (Sigma-L-6876)
and 150U/mL of mutanolysin (Sigma M-9901), and mix-
ture was incubated for one hour at 37 °C. The remaining
extraction procedures followed Qiagen DNA Mini kit
(Qiagen, UK) manufacturer’s instructions.
Purified DNA extracts were subjected to sequential
triplex qPCR assay for detecting 21 pneumococcal cap-
sular serotypes for the African scheme as previously de-
scribed [29]. CSF specimens with CT values ≤32 were
further subjected to conventional multiplex PCRs also
described elsewhere [30, 31].
Whole-genome sequencing
Whole-genome sequencing was performed on nine puri-
fied pneumococcal isolates cultured from CSF specimens.
All the isolates could not be sequenced due to cost consid-
erations. Sequencing was performed on the illumina
Miseq platform following a NexteraX library preparation
step. Genomic data was analysed using the nullarbor pipe-
line (https://github.com/tseemann/nullarbor), which con-
firmed the species of the isolates, inferred MLST types,
reported the presence of resistance genes and extracted a
core genome. Draft genome assemblies for the nine out-
break strains were generated using spades (kmers: 21, 33,
55, 77, 99 and 127). To illustrate the phylogenetic relation-
ship of the outbreak ST303 isolates, we included nine
archived ST303 draft pneumococcal genome assemblies
[32]. The assembled ST303 genomes from the pneumo-
coccal outbreak strains and the draft genomes were com-
pared against the P1031 pneumococcal reference genome;
a pneumococcal historical isolate from Ghana [33].
Contigs were mapped against the reference and SNVs
were called from the core genome using parsnp [34]. The
pneumococcal genome sequences are available on the
European Bioinformatics Institute (EBI) database under
study accession PRJEB15437 at http://www.ebi.ac.uk/ena/
data/view/PRJEB15437.
Data management
Demographic and clinical data of suspected cases were
collected with designed case report forms and entered
into Microsoft Excel and an EPI Info database tool.
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Demographic and clinical data of the cases were extracted
into a line list. The Excel data sets from the health facilities
were imported and merged into a Microsoft Access data-
base. Pathogen detection, serotyping and serogrouping
data from qPCR and other methods were imported and
merged with demographic and clinical data in the custom-
ized Microsoft Access database. Antibiotic and antibiogram
data were also entered into the customized Microsoft Ac-
cess database. Data analysis was carried out using Graph-
Pad Prism, R statistics tool (version 3.2.4) for Windows
and Microsoft Excel. The maps were generated using QGIS
v1.0 software using Geographical Position System (GPS)
coordinates from the US Geographical Survey (USGS)
https://www.usgs.gov.
Results
The nationwide weekly incidence of meningitis rose
from <5 cases/100,000 people in the 49th week of 2015
to 350 cases/100,000 people in the 7th week of 2016.
Between 2 December 2015 (49th week) and 26 February
2016 (9th week), there were 886 suspected meningitis
cases reported. A flow chart of the CSF specimens col-
lected, tested and the outcomes are summarised in Fig. 1.
Overall, 64 % (567/886) of CSF specimens were tested
by rapid test, culture and/or qPCR. Meningitis was con-
firmed in 23.8 % (135/567). Pneumococcus, meningo-
coccus and GBS accounted for 77 % (104/135), 22 %
(30/135) and 1 % (1/135) of the confirmed cases of men-
ingitis. One CSF was positive for both meningococcus
and pneumococcus, an unusual finding probably due to
contamination (Fig. 1).
The characteristics of the patients with suspected and
confirmed meningitis are summarised in Table 1. The
patients’ median age was 20 years (IQR 13 and IQR 32)
and the range was 9 months to 98 years. 15 to 29 year
olds accounted for 40 % of the suspected and confirmed
cases. Less than 5 % of the suspected and confirmed
cases were among children less than 4 years old who
would likely have received PCV13 (Table 1).
Although suspected meningitis patients were reported
across the whole region, the epicenter of the outbreak was
in four contiguous districts; Jaman North, Tain, Wenchi
and Techiman municipal (Fig. 2a). There were 363 sus-
pected meningitis cases per 100,000 people in Jaman North,
more than double that reported in Tain with 156 per
100,000 people. Although Jaman North had the highest rate
of suspected cases, Tain and Wenchi had the highest rates
of confirmed cases. There were 25, 20, 11 and 10 confirmed
cases per 100,000 people in Tain, Wenchi, Jaman North
and Techiman Municipal, respectively (Fig. 2a/b). The
number of confirmed cases declined after the 6th week of
2016, but those of suspected cases increased up to the 8th
week of 2016 as shown in Additional file 1. The meningitis
outbreak peaked at different weeks across the hardest hit
districts (Additional file 1). Tain district crossed the epi-
demic threshold of 10 suspected cases per 100,000 popula-
tion in week 53 of 2015 whereas Wenchi and Jaman North
district crossed the epidemic threshold in weeks 3 and 6 of
2016 respectively (Additional file 1).
Pneumococcus was the sole or leading pathogen
across all districts with the exception of Jaman North
district where meningococcus was the dominant pathogen
Fig. 1 Summary of CSF specimen collection and processing
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accounting for 63 % (7/11) of confirmed cases (Fig. 2b).
Pneumococcus was the leading pathogen from the 52nd
week of 2015 to the 9th week of 2016 (Fig. 3a). Meningo-
coccus was detected between weeks 2 and 7 of 2015. GBS
was cultured from a CSF specimen in week 7 of 2015
(Fig. 3a).
The molecular and latex serotyping results by age
group are summarised in Table 2. A tenth (10/104) of
the pneumococci detected by PCR were either non-
typeable by PCR or had a High Ct for molecular typing.
Forty-five pneumococci could not be typed as the isolate
and/or CSF was not available for serotyping. Serotype 1
accounted for 78 % (38/49) of the serotyped pneumo-
cocci. The distribution of the other serotypes was 12 %
(6/49) serotype 12 F, 4 % (2/49) serotype 35B, 2 % (1/49)
serotype of each, serotype 6A/6B, serotype 7 F and sero-
type 3. The only infant (10.8 month old) with confirmed
pneumococcal meningitis had a serotype 35B infection,
a non-PCV13 serotype. Serotype 1 was the only pneumo-
coccal serotype detected among patients between four and
29 years old (Fig. 3d). In contrast, serotype 12 F, also a
non-PCV13 serotype, was confirmed among cases
aged ≥30 years. The serotype 12 F pneumococcal
strains were detected across five districts including
Tain in weeks 3 and 5 of 2015. The two serotype 35B
strains were detected in Dormaa in week 8 of 2016
(Fig. 3c). Of the 20 meningococci that could be sero-
typed, 80 % (16/20) were serogroup W, 5 % (1/20) was
a serogroup C and 15 % (3/20) could not be grouped
by the real time PCR serotyping panel that includes
serogroups A, B, C, W, X and Y.
A tenth (75/786) of the patients with suspected meningitis
and a known outcome died. Among the confirmed cases,
death was reported among 24 % (33/135) of the patients
(Table 1). Amongst the deaths, the average length of time
before reporting was 1.7 days and the average length of stay
between admission and death was 2.3 days. The case fatality
rates for confirmed meningococcal and pneumococcal men-
ingitis were 36 % (8/22) and 29 % (25/85) respectively. The
eight-year-old child with GBS meningitis survived.
Pneumococcal and meningococcal isolates were con-
firmed at the WHO RRL and underwent antibiotic suscep-
tibility testing by disc diffusion and E-test [24]. Seventeen
pneumococcal isolates from CSF were available for anti-
microbial susceptibility testing by disc diffusion and E-test
methods for commonly prescribed antibiotics in the sub-
region following CSLI guidelines [24]. The antibiogram of
the isolates, serotype and the basic patient characteristics
are summarised in Additional file 2. All the pneumococcal
isolates tested were fully susceptible to ceftriaxone, vanco-
mycin, chloramphenicol, clindamycin, erythromycin and
rifampin. In contrast, 76 % (13/17) of the strains were
resistant or had intermediate resistance to trimethoprim-
sulfamethoxazole. Over 80 % (14/17) of the isolates were
resistant to tetracycline. Resistance to penicillin was
found in two isolates, both serotype 1 strains. These
two serotype 1 strains were also resistant to trimethoprim-
sulfamethoxazole and tetracycline. Both serotype 35B
strains were fully susceptible to all the antibiotics
screened. Antimicrobial activity in the CSF specimens
was assessed by the disc diffusion antibiotic bioassay.
Antimicrobial activity was detected in 1.5 % (5/325) of
Table 1 Patient characteristics and outcome
Characteristic Category Suspected Cases
n (%)
Confirmed Cases
n (%)
S. Pneumoniae
n (%)
N. Meningitidis
n (%)
Group B Streptococcus
n (%)
Mixed
pathogen
Gender Female 458 (51.6) 55 (40.4) 43 (41.3) 10 (33.3) 1 (10) 1 (10)
Male 348 (39.2) 54 (39.7) 42 (40.3) 12 (40.0) 0 (0) 0 (0)
Unknown 80 (9.0) 27 (19.8) 19 (18.2) 8 (26.6) 0 (0) 0 (0)
Age <1 11 (1.2) 2 (1.4) 2 (1.9) 0 (0) 0 (0) 0 (0)
1–4 26 (2.9) 4 (2.9) 3 (2.8) 1 (3.3) 0 (0) 0 (0)
5–14 174 (19.6) 35 (25.7) 30 (28.8) 4 (13.3) 1 (100) 0 (0)
15–29 354 (39.9) 44 (32.3) 31 (29.8) 12 (4) 0 (0) 1 (100)
30–59 203 (22.9) 19 (13.9) 16 (15.3) 3 (10) 0 (0) 0 (0)
>60 37 (4.1) 5 (3.6) 3 (2.8) 2 (6.6) 0 (0) 0 (0)
Unknown 81 (9.1) 27 (19.8) 19 (18.2) 8 (26.6) 0 (0) 0 (0)
January 267 (30.1) 74 (54.4) 58 (55.7) 15 (5) 0 (0) 1 (100)
February 499 (56.32) 30 (22.0) 22 (21.1) 7 (23.3) 1 (100) 0 (0)
Unknown 100 (11.28) 27 (19.8) 19 (18.2) 8 (26.6) 0 (0) 0 (0)
Outcome Alive 711 (80.2) 76 (55.8) 60 (57.6) 14 (46.6) 1 (10) 1 (100)
Dead 75 (8.4) 33 (24.2) 25 (24.0) 8 (26.6) 0 (0) 0 (0)
Unknown 100 (11.2) 27 (19.8) 19 (18.2) 8 (26.6) 0 (0) 0 (0)
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the CSF specimens tested. A pathogen was detected in
2 of the 5 CSF specimens with antimicrobial activity.
Whole genome sequencing was performed on nine ran-
domly selected pneumococcal isolates. The predominant
lineage was ST303 (n = 7) found among serotype 1 isolates.
The serotype 3 and 7 F strains belonged to ST700 and
ST2833 lineages respectively. The phylogenetic tree of our
outbreak strains showed that the ST303 isolates formed
two separate clusters (Fig. 4a). To illustrate the diversity of
ST303 within the outbreak, the phylogeny was recon-
structed from the ST303 outbreak strains and other previ-
ously sequenced ST303 pneumococcal genomes (Fig. 4b).
Four outbreak isolates (BAR_GH_2016_10, 13, 14 and 17)
clustered on a clade characterized by a long branch
from the closest relatives and short branches within
the clade. The average pairwise distance between strains on
this branch was 18 core genome SNVs. BAR_GH_2016_16
bore similarity to a cluster of ST303 previously isolated
from Togo, a neighboring country, east of Ghana.
BAR_GH_2016_7 and 18 presented as outgroups in our
phylogeny without any marked identity to other isolates.
Discussion
To our knowledge, this is the first large pneumococcal
meningitis outbreak to occur in Ghana since the early
2000s and the first report of a pneumococcal meningitis
Fig. 2 The geographical distribution of the suspected and confirmed meningitis cases in Brong Ahafo region. The districts are shaded by
suspected meningitis per 100,000 population and the pie charts representing the proportion of confirmed cases (a). The districts are shaded by
the confirmed cases per 100,000 population and the pie charts represent the distribution of pathogens (b). The maps were generated using QGIS
v1.0 software using Geographical Position System (GPS) coordinates from the US Geographical Survey (USGS) https://www.usgs.gov
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outbreak outside of the Northern regions of Ghana. [16].
Between 2004 and 2013, there were on average 600 cases
of suspected and confirmed meningitis reported per year
in Ghana [35]. However, at least 886 cases of suspected
meningitis, probable and confirmed meningitis had been
reported in Brong Ahafo Region alone by the 9th week
of 2016. Although pneumococcal meningitis affected
individuals of all ages, nearly 60 % of the cases were
among individuals between 5 and 29 years old. Nearly
80 % of the confirmed pneumococcal meningitis cases
were attributed to serotype 1. Whole genome sequen-
cing of pneumococcal isolates showed that the serotype
Fig. 3 The distribution of pathogens by week and age. The distribution of pathogens by week (a) and age (b). The distribution of pneumococcal
serotypes by week (c) and age (d)
Table 2 Distribution of pneumococcal serotypes which caused meningitis by age group
Age Group 1 12 F 3 35B 6A/6B 7 F aHigh Ct value bNontypeable cNot serotyped Total
<1 0 0 0 1 0 0 0 1 0 2
1–4 1 0 0 0 0 0 0 1 1 3
5–14 8 0 0 0 0 1 0 1 20 30
15–29 12 0 0 0 0 0 0 2 17 31
30–59 5 3 1 1 0 0 0 0 6 16
>60 0 0 0 0 1 0 1 0 1 3
Unknown 12 3 0 0 0 0 2 2 0 19
Grand Total 38 6 1 2 1 1 3 7 45 104
aThese CSF had a Ct value >32 and <36 for pneumococcal detection which is above the threshold for molecular serotyping
bThe pneumococci could not be serotyped using molecular techniques which detect a limited panel of serotypes
cThe CSF specimens and isolates were not available for serotyping
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1 strains from the outbreak belonged to the hypervirulent
ST217 clonal complex [14, 33]. Although the increasingly
important role of pneumococcus in meningitis outbreaks
has been reported previously [14, 16, 17], the occurrence
of a pneumococcal meningitis outbreak outside the men-
ingitis belt post PCV13 introduction is alarming and high-
lights the need for vigilant monitoring of pneumococcal
invasive disease in Ghana.
Implemented pneumococcal vaccination strategies in
Ghana and across Africa almost exclusively target infants.
The huge burden of invasive pneumococcal disease among
children less than 5 years old globally, together with cost
considerations and the lack of data on the burden of disease
in other age categories, probably led to policies that protect
the youngest and most vulnerable. PCV13 was introduced
in Ghana in 2012 and includes serotype 1, which is prob-
ably why less than 5 % of pneumococcal meningitis cases
were among children less than five years old. In northern
Ghana, between 1998 and 2003 prior to the introduction of
PCV into the expanded programme of immunization (EPI),
the highest incidence of pneumococcal meningitis was
found among infants with an annual incidence of 43 cases
per 100,000 population [16]. Likewise in neighboring
Burkina Faso and Togo between 2002 and 2006, 36 %
of pneumococcal meningitis cases were among children
less than 5 years old prior to the introduction of pneumo-
coccal conjugate vaccines [3].
PCVs induce herd immunity, markedly reducing vaccine
serotype carriage and invasive pneumococcal disease
amongst both vaccinated and unvaccinated individuals
[36]. However, the high prevalence of pneumococcal
serotype 1 meningitis among older children (≥5 years)
and adults heralds the need to revisit the current policy
and to include all age groups in high-risk populations.
Kenya has recorded success with an extensive catch up
campaign with PCV-10 for all children less than five
years old; there was a 66 % decline in carriage of vaccine se-
rotypes in individuals older than 5 years [37]. If the cost of
rolling out PCV13 across all age groups is considered an
obstacle, the possibility of implementing a pneumococcal
serotype 1 monovalent conjugate vaccine following the
model used for meningococcus could be explored. How-
ever, it is important to note that the national PCV13 cover-
age in Ghana was only 41 % and 68 % in 2012 and 2013,
Fig. 4 Phylogenetic analysis of outbreak strains. Phylogenetic tree of outbreak strains with antibiogram and patient data (a). Phylogenetic analysis
of serotype 1 outbreak ST303 strains and historical West African ST303 strains. A novel clade of ST303 serotype distinct from the historic West
African ST303 strains is evident (b)
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respectively, which may be inadequate to induce herd im-
munity. Although PCV13 coverage rose to 85 % in 2014,
maintenance of this coverage and close monitoring of vac-
cine serotype carriage and disease are needed. Furthermore,
the occurrence of serotype 12 F and 35B meningitis, both
non-PCV13 serotypes, is also a cause for concern. Serotype
12 F in particular is emerging as an important cause of in-
vasive pneumococcal disease with the propensity to cause
outbreaks [38–40].
Leimkugel and colleagues reported that ST303 accounted
for 55 % of the serotype 1 strains responsible for a meningitis
outbreak in northern Ghana in 2001–2003. All the other
serotype 1 strains were clonally related and belonged to the
ST217 clonal complex [16]. Likewise, closely related serotype
1 lineages belonging to the ST217 clonal complex were the
predominant strains in the highly lethal meningitis epidemic
between 2003 and 2004 in Burkina Faso, which borders
northern Ghana [14]. All seven serotype 1 strains se-
quenced in the 2015–2016 Ghana meningitis outbreak
belonged to ST303 and at least four are very likely to
be the product of a recent clonal expansion within ST303.
These strains, which belong to a unique clade, are likely to
have diverged from the other previously sequenced ST303
lineages, including strain P1031 from a previous meningitis
outbreak in Ghana [16].
All the pneumococcal isolates were fully susceptible to
chloramphenicol and ceftriaxone. The recommended treat-
ment for pneumococcal meningitis is vancomycin and a
third generation cephalosporin (ceftriaxone and cefotaxime)
or rifampin. Similarly, the recommended antimicrobial
therapy for meningococcal meningitis is ceftriaxone or
cefotaxime although penicillin G, ampicillin and chlor-
amphenicol are also effective treatments [41]. It is re-
assuring that all the pneumococcal isolates tested were
fully susceptible to ceftriaxone and chloramphenicol.
Two isolates were resistant to three antibiotics, penicillin
G, trimethoprim-sulfamethoxazole and tetracycline. The
only meningococcal isolate available for antimicrobial sus-
ceptibility testing showed intermediate resistance to chlor-
amphenicol. However, more isolates would have to be
tested to confirm the prevalence of reduced susceptibility
within the population.
This study has shown that pneumococcal outbreaks
caused by closely related strains can reoccur within West
Africa. Although the factors that drive pneumococcal
meningitis outbreaks are not well understood, it is likely
that environmental factors play an important role. As with
meningococcal meningitis outbreaks, the highest inci-
dence occurs during the dry season (December to March)
[1–3] in West African countries. Greenwood has sug-
gested that the hot dry conditions damage the mucosal
defences increasing vulnerability to invasive pneumococcal
and meningococcal disease [42]. Although this is a
plausible contributing factor, there are likely to be other
environmental and biological determinants of pneumo-
coccal meningitis outbreaks that need to be investigated.
Conclusions
The results reported here are of great public health im-
portance and summarised as follows: 1) Pneumococcus
continues to be of increasing importance in meningitis
outbreaks, even outside the meningitis belt; 2) In a post-
PCV13 era, pneumococcal serotype 1 still has the propen-
sity to cause large outbreak; 3) Non-vaccine serotypes such
as serotype 12 F can be important causes of meningitis dur-
ing outbreaks. The reoccurrence of pneumococcal serotype
1meningitis outbreaks in the sub-region highlights the need
for a monovalent vaccine targeted to older non-infant
children and adults in high-risk populations. Clear guide-
lines on the prevention, control and treatment of pneumo-
coccal meningitis outbreaks need to be developed for West
Africa. Meningitis surveillance and monitoring is needed
even in regions that do not typically experience outbreaks
as well as a careful review of the geographical areas previ-
ously considered to be at high risk for meningitis outbreaks
within the West African sub-region.
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